MATINAS BIOPHARMA HOLDINGS, INC. Research and Development in Process
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Research and Development in Process of $1.20 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-15
- MATINAS BIOPHARMA HOLDINGS, INC. research and development in process for the quarter ending 2021-12-31 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. research and development in process for fiscal 2021 was $1.20M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.20M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $1.20M 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |